Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Add as a preferred source on Google
BURLINGTON, Mass., March 01, 2018 -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer and Troy Ignelzi, chief financial officer of scPharmaceuticals, will present at the Cowen 38th Annual Health Care Conference at 10:40 a.m. ET on Wednesday, March 14, 2018, at the Boston Marriott Copley Plaza in Boston, MA.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.scpharmaceuticals.com for ninety days.
About scPharmaceuticals
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (IV) delivery.
Contacts:
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
[email protected]
Christopher F. Brinzey
Westwicke Partners, 339-970-2843
[email protected]
